ライフサイエンスコーパス: sialyl

1 , 6'-sialyllactosamine, disialyltetraose, 3'-sialyl-3-fucosyllactose, sialyllacto-N-tetraose-a, sialy

2 nation of both peripheral node addressin and sialyl 6-sulfo Lewis X in high endothelial venules, cons

3 Its epitope overlaps with sialyl 6-sulfo Lewis X, an L-selectin recognition determ

4 ulfated oligosaccharide, which overlaps with sialyl 6-sulfo Lewis X, the L-selectin recognition deter

5 was used to generate the C8-iodide, the key sialyl acceptor (electrophile).

6 ant-rat model; and (v) expression of the LOS sialyl acceptor is altered in cells grown without exogen

7 ; (iv) a nanA mutant hypersialylates its LOS sialyl acceptor, corresponding to an apparent increased

8 with the 5-azido-d-glycero-d-gulo-configured sialyl adamantanylthioglycoside at -78 degrees C are sel

9 rmed that the major sialylated species has a sialyl-alpha-(2-3)-lactosyl extension off the distal hep

10 up strongly reduced the inhibitory effect of sialyl alpha2-->1 Sph on GM3-dependent adhesion, FAK, an

11 Incubation of B16 cells with 0.5-10 microM sialyl alpha2-->1 Sph or 1-5 microM lyso-GM3 reduced GM3

12 ted by clusters of GM3 in GSD, is blocked by sialyl alpha2-->1 Sph or lyso-GM3.

13 Analogues with N-substitution of Sph in sialyl alpha2-->1 Sph, other lyso-phospholipids, and gal

14 .5-10 microM did not show the same effect as sialyl alpha2-->1 Sph.

15 ted from B16 cells was inhibited strongly by sialyl alpha2-->1 Sph.

16 mpound so far found with these properties is sialyl alpha2-->1 sphingosine (Sph).

17 the normally cryptic core Tn (GalNAc), STn (sialyl alpha2-6 GalNAc), and TF (Gal beta1-3 GalNAc) car

18 To clarify the role of milk oligosaccharide sialyl(alpha2,3)lactose (3SL) in intestinal physiology a

19 Sialyl and especially sulfated glycans are difficult to

20 of two independent ancestral genes encoding sialyl- and galactosyltransferase activity.

21 mately 66% of the glycan pool, with alpha2-6-sialyl core 1 being the predominant O-glycan structure i

22 -O-oxazolidinone-protected 1-adamantanylthio sialyl donor high alpha-selectivities could be achieved

23 UMP-NeuAc, which was found to be an inactive sialyl donor.

24 These sialyl donors gave high yields and excellent alpha-anome

25 ure of the synthetic approach was the use of sialyl donors that were protected with a C-5 trifluoroac

26 mplex, and hybrid subtypes such as sulfo and sialyl forms.

27 A series of sialyl fucosyl poly-N-acetylgalactosamine gangliosides w

28 cbeta1,3Galalpha-O-Me] structures containing sialyl, fucosyl, sulfo, methyl, or fluoro substituents b

29 nalyzed the expression of sialyl Lewis X and sialyl-fucosylated core 2 O-glycan (CHO-131 antigen), re

30 effects for hydrolysis of sialyl-lactose and sialyl-galactose were 1.016 +/- 0.011 and 1.015 +/- 0.00

31 beta-dideuterium and primary 13C effects for sialyl-galactose were 1.060 +/- 0.008 and 1.032 +/- 0.00

32 trate, sialyl-lactose, and a slow substrate, sialyl-galactose, in both acid-catalyzed solvolysis and

33 bopentaose (Gb5), fucosyl-Gb5 (Globo H), and sialyl-Gb5 (SSEA4) by using overexpressed glycosyltransf

34 ,3Galbeta1,3GalNAcalpha unit of O-glycans, 3-sialyl globo unit of glycolipids, and sialylated macromo

35 ngliosides sialyl-lactotetraosylceramide and sialyl-globotetraosylceramide, and the sulfated glycosph

36 The resulting 77 sialyl glycans were purified and quantified, characteriz

37 em to generate alpha2-3- and alpha2-6-linked sialyl glycans with 16 modified sialic acids.

38 the preparative synthesis of representative sialyl glycoconjugates has been demonstrated.

39 SSEA-4, a sialyl-glycolipid, has been commonly used as a pluripote

40 opoiesis may be regulated not by the hepatic sialyl glycoproteins, but by the ST6Gal-1 that was relea

41 ifferentially O-protected N-nitroso-N-acetyl sialyl glycosides and of isotopic labeling studies.

42 dative deamination of the N-nitroso-N-acetyl sialyl glycosides leading with overall retention of conf

43 n termini are shown to be sparsely capped by sialyl groups which, if present, are exclusively (alpha2

44 loped on the basis of the equilibration of O-sialyl hydroxylamines by reversible homolytic scission o

45 rus HA with bivalent displays of the natural sialyl-LacNAc ligand.

46 The bivalent scaffolds presented two sialyl-LacNAc ligands in 23-101 A distance.

47 s as ST3[Galbeta1,4GlcNAc] < or = alpha1,3FT[sialyl-LacNAc] < beta1,3GlcNAcT.

48 tterns range from common sialyl Lewis(x) and sialyl lacto-chains to chemically functionalized carbohy

49 uced enzyme activity and growth rate on 2-3' sialyl lactose compared to the wild type.

50 erated sialic acid from colominic acid (2-8' sialyl lactose).

51 demonstrated activity on both 2-3' and 2-6' sialyl lactose, while NanH demonstrated activity only on

52 hile NanH demonstrated activity only on 2-3' sialyl lactose.

53 rimary 13C isotope effects for hydrolysis of sialyl-lactose and sialyl-galactose were 1.016 +/- 0.011

54 The beta-dideuterium isotope effect for sialyl-lactose in the acid hydrolysis reaction was 1.113

55 effects were measured for a good substrate, sialyl-lactose, and a slow substrate, sialyl-galactose,

56 These findings identify sialyl-lactotetra as a promising marker of undifferentia

57 ion of hiPSC into hepatocyte-like cells, the sialyl-lactotetra epitope was rapidly down-regulated and

58 A high cell surface expression of sialyl-lactotetra on hESC and human induced pluripotent

59 ochemistry showed distinct cell surface anti-sialyl-lactotetra staining on all seven hESC lines and t

60 id glycosphingolipids, like the gangliosides sialyl-lactotetraosylceramide and sialyl-globotetraosylc

61 ) and sialyl Le(x) or domain antibody 25 and sialyl Le(x) acted synergistically.

62 unoblotting with an antibody specific to the sialyl Le(x) carbohydrate epitope detected expression on

63 Combinations of Le(b) and sialyl Le(x) or domain antibody 25 and sialyl Le(x) acte

64 acetylgalactosamine gangliosides without the sialyl-Le epitope, collectively termed, have been shown

65 Sulfated forms of sialyl-Le(X) containing Gal-6-SO(4) or GlcNAc-6-SO(4) ha

66 ll adhesion assays, anti-Le(x), but not anti-sialyl-Le(x) monoclonal antibodies, inhibited the format

67 FucT-VI catalyzes primarily the synthesis of sialyl-Le(x).

68 two isomeric monofucosyl antigens, VIM2 and sialyl-Le(x).

69 se E-selectin, although they did not express sialyl-Le(X).

70 a mucin, isomeric oligosaccharide sequences, sialyl-Lea- and sialyl-Lex-active, could be resolved by

71 ted by protein-specific O-glycosylation with sialyl Lewis A (sLe(a)).

72 hat human M cells preferentially display the sialyl Lewis A antigen.

73 electin ligand components sialyl Lewis x and sialyl Lewis a are oncodevelopmental antigens involved i

74 e inhibited the binding of sialyl Lewis X or sialyl Lewis A oligosaccharides to E-selectin.

75 , E- and P-selectins, are thought to mediate sialyl Lewis A/X-dependent hematogenous cancer metastasi

76 P-selectin blocking monoclonal antibodies or sialyl Lewis tetrasaccharide inhibits the enhanced adher

77 Moreover, sialyl Lewis x (17) was synthesized via the enzymatic fu

78 osylated glycan receptors, including 6-sulfo-sialyl Lewis x (6-sulfo-sLe(x)).

79 L-selectin binds to the sulfated sialyl Lewis x (6-sulfo-sLex) epitope present on O-glyca

80 pating in the synthesis of core 2-associated sialyl Lewis x (C2-O-sLe(x)), a ligand involved in selec

81 idue with a core 2-based O-glycan expressing sialyl Lewis x (C2-O-sLe(x)).

82 an adjacent core-2-based O-glycan expressing sialyl Lewis x (C2-O-sLe(x)).

83 de 1) diminishes the formation of the glycan sialyl Lewis X (Neu5Acalpha2-3Galbeta1-4(Fucalpha1-3) Gl

84 ied by the emergence of the CSLEX-1 epitope, sialyl Lewis x (NeuAcalpha2,3Galbeta1,4(Fucalpha1,3)GlcN

85 E-selectin glycoprotein ligand(s); distinct sialyl Lewis X (or HECA-452 antigen)-bearing membrane pr

86 ual sulfated tetrasaccharide epitope 6-sulfo sialyl Lewis x (Siaalpha2-->3Galbeta1-->4[Fucalpha1-->3]

87 the canonical E-selectin binding determinant sialyl Lewis X (sLe(X)) and display markedly greater adh

88 A. phagocytophilum binding to sialyl Lewis x (sLe(x)) and other sialylated glycans tha

89 A sialyl Lewis X (sLe(x)) mimetic compound, 2-(trimethylsi

90 ligand sulfotransferase (LSST) forms 6-sulfo sialyl Lewis x (sLe(x)) on both core 2 branch and MECA-7

91 Sialyl Lewis X (sLe(X)) on prostate cancer (PCa) cells i

92 Clustered presentation of sialyl Lewis X (sLe(X)) on tumor cell mucins is thought

93 lpha1-3-fucosylated selectin ligands such as sialyl Lewis x (sLe(x)), although monoclonal antibodies

94 ty by ablating N-acetyllactosamine (LacNAc), sialyl Lewis X (sLe(X)), and related lectin ligands on e

95 hesion proteins P- and L-selectin binding to sialyl Lewis X (sLe(X))-containing ligands, and the myos

96 an intragranulocytic bacterium that utilizes sialyl Lewis x (sLe(x))-modified P-selectin glycoprotein

97 osylated to form glycan determinants such as sialyl Lewis x (sLe(x)).

98 Sialyl Lewis X (sLex) mimetics that can function as sele

99 igand-1 (PSGL-1), which displays appropriate sialyl Lewis x (sLex)-like carbohydrate determinants for

100 erases that construct the glycan determinant sialyl Lewis x (sLex).

101 tment resulted in dose-dependent ablation of sialyl Lewis X and CHO-131 antigen expression on PSGL-1,

102 eactive with HECA-452, a mAb that recognizes sialyl Lewis X and related structures.

103 The selectin ligand components sialyl Lewis x and sialyl Lewis a are oncodevelopmental

104 ere inhibited, we analyzed the expression of sialyl Lewis X and sialyl-fucosylated core 2 O-glycan (C

105 re colon cancer HT29 cells by using multiple Sialyl Lewis X antibodies (aSlex)-conjugated PAMAM dendr

106 ugh it has been shown to more effective than sialyl Lewis x at blocking the L-selectin-GlyCAM-1 inter

107 ts, we propose possible pathways for 6-sulfo sialyl Lewis x biosynthesis and suggest that sulfation m

108 and glycosphingolipid structures displaying sialyl Lewis X epitopes as potential E-selectin ligands

109 ranose) action by contrasting the effects on sialyl Lewis X expression displayed by P-selectin glycop

110 of soluble complement receptor-1 (sCR1) was sialyl Lewis x glycosylated (sCR1sLex) to inhibit comple

111 Additional benefit was conferred by sialyl Lewis x glycosylation of the unmodified parent sC

112 It has been established that sialyl Lewis x in core 2 branched O-glycans serves as an

113 tes, although less than CHO cells expressing sialyl Lewis x in core 2 branched O-glycans.

114 nsfected cells carried comparable amounts of sialyl Lewis x in extended core 1 and core 2 branched O-

115 These results indicate that sialyl Lewis x in extended core 1 O-glycans can function

116 In a rolling assay, CHO cells expressing sialyl Lewis x in extended core 1 O-glycans supported a

117 To determine the roles of sialyl Lewis x in extended core 1 O-glycans, Chinese ham

118 critical function of N-glycan-linked 6-sulfo sialyl Lewis X in L-selectin-dependent lymphocyte homing

119 III.H cells expressing the highest amount of sialyl Lewis X in shorter N-glycans died in lung blood v

120 In order to determine the roles of sialyl Lewis X in tumor metastasis, mouse melanoma B16-F

121 Sulfation of GlcNAc within sialyl Lewis x is a crucial modification for L-selectin

122 ied a class of N-glycans bearing the 6-sulfo sialyl Lewis X L-selectin ligand in high endothelial ven

123 Sialyl Lewis X moieties are critical for ligand activity

124 at adding fucose to human Tregs, forming the Sialyl Lewis X moiety on P-selectin glycoprotein ligand-

125 to recognize both nonsulfated and 6-sulfated sialyl Lewis X on core 2 branched O-glycans, and MECA-79

126 AcT) enabled the construction of the 6-sulfo sialyl Lewis x on extended core1 O-glycans, recapitulati

127 phocytes and the carbohydrate ligand 6-sulfo sialyl Lewis X on high endothelial venules.

128 sulfated carbohydrate structures (6-sulfated sialyl Lewis x or 6-sulfo-sLex) as a recognition determi

129 g the same sequence inhibited the binding of sialyl Lewis X or sialyl Lewis A oligosaccharides to E-s

130 alpha1, 3-fucosyltransferase III to express sialyl Lewis X structures.

131 This binding requires the sialyl Lewis x sugar moiety to be placed on both O- and

132 n of HL-60 and B16 melanoma cells expressing sialyl Lewis X to E-selectin was also inhibited by the p

133 utant mice, whereas the amount of unsulfated sialyl Lewis X was much greater.

134 kingly, bonds between L-selectin and 6-sulfo-sialyl Lewis X were impervious to ramp rate changes.

135 for a sulfated-glycan binding site (6-sulfo-sialyl Lewis x) on peripheral node addressin.

136 and fucosylated alpha2-3 glycans (including sialyl Lewis x), both of which may be important receptor

137 rate structural analysis showed that 6-sulfo sialyl Lewis X, a dominant ligand for L-selectin, was al

138 This epitope overlaps with 6-sulfo sialyl Lewis x, a recognition determinant for L-selectin

139 m the neutrophil surface during rolling on a sialyl Lewis x-coated planar surface at physiological sh

140 -selectin on neutrophils during rolling on a sialyl Lewis x-coated surface that involves mechanical f

141 We tested this hypothesis using sialyl Lewis X-dependent B16 melanoma lung targeting and

142 n the lung vasculature plays a major role in sialyl Lewis X-dependent cancer cells targeting to the l

143 n E/P-selectin doubly deficient mutant mice, sialyl Lewis X-expressing B16 melanoma cells colonized t

144 carbohydrate-dependent lung colonization of sialyl Lewis X-expressing B16-FTIII-M cells in E/P-selec

145 ctable sulfation of GlcNAc in the context of sialyl Lewis x.

146 that comprise structural motifs derived from sialyl Lewis x.

147 lanoma and human lung tumor cells expressing sialyl Lewis X.

148 ent groups based on the expression levels of sialyl Lewis X.

149 lung nodules as B16-FTIII.N cells which lack sialyl Lewis X.

150 various functional oligosaccharides, such as sialyl Lewis X.

151 humans through the generation of functional sialyl Lewis X.

152 th the saccharides sialyl Lewis(x) (sLe(x)), sialyl Lewis(a) (sLe(a)), and sulfated Lewis(x) (HSO(3)L

153 (MB) functionalized with the selectin ligand sialyl Lewis(a) individually (MBsLea) or dually with sLe

154 A expression) and new biomarkers (levels of sialyl Lewis(a), Lewis(x), and Aspergillus oryzae lectin

155 l bubbles (MB(CTL)) bore surface Lewis(x) or sialyl Lewis(c).

156 Sialyl Lewis(x) (sLe(x)) and Lewis(x) (Le(x)) are known

157 Monomeric sialyl Lewis(X) (sLe(x)) and sLe(x)-like oligosaccharide

158 have reported that microspheres coated with sialyl Lewis(x) (sLe(x)) interact specifically and roll

159 -terminus of PSGL-1 through recognition of a sialyl Lewis(x) (SLe(x)) moiety linked to a properly pos

160 Binding of the P-, L-, and E-selectins to sialyl Lewis(x) (sLe(x)) retards circulating leukocytes,

161 nanometer-scale polymer construct containing sialyl Lewis(x) (sLe(x)) that is found on the surface of

162 f L-selectin and the minimal selectin ligand sialyl Lewis(x) (sLe(x)) to interact with postcapillary

163 res functionalized with the selectin ligand, sialyl Lewis(X) (sLe(X)), and an antibody against ICAM-1

164 find that beads coated with the saccharides sialyl Lewis(x) (sLe(x)), sialyl Lewis(a) (sLe(a)), and

165 ds are glycosylated with the tetrasaccharide sialyl Lewis(x) (sLe(x)), which contributes to bond affi

166 However, the only millimolar affinity of sialyl Lewis(x) (sLe(x)), which is the common tetrasacch

167 ted in a cell-free system; it was shown that sialyl Lewis(x) (sLe(x))-coated microspheres roll over E

168 omplex with its prime glycan target 6'-sulfo sialyl Lewis(x) A canonical motif for sialic acid recogn

169 nhibitors of selectin binding to immobilized sialyl Lewis(X) and of cell adhesion to immobilized sele

170 introduced glyco-patterns range from common sialyl Lewis(x) and sialyl lacto-chains to chemically fu

171 ide but does not bind to GM1, GD1a, GT1b, or sialyl Lewis(X) antigens.

172 egulation of endothelial selectins that bind sialyl Lewis(x) ligands and activation of beta(2)-integr

173 Furthermore, saliva/sialyl Lewis(X) mediated signaling enhanced intracellula

174 d SIGNR7 binds preferentially to the 6-sulfo-sialyl Lewis(x) oligosaccharide, whereas SIGNR2 binds al

175 volving the binding of P- and L-selectins to sialyl Lewis(X) oligosaccharide-containing ligands.

176 Here we show that binding of E-selectin to sialyl Lewis(x) on L-selectin and PSGL-1 drives their co

177 T, that directs the synthesis of the 6-sulfo sialyl Lewis(x) on L-selectin counterreceptors CD34, Gly

178 intracellular signals elicited by binding of sialyl Lewis(X) present on salival mucins to l-selectin

179 ger than that for integrin binding to RGD or sialyl Lewis(x) to E-selectin.

180 The selectin ligand sialyl Lewis(x) was conjugated to the microbubble surfac

181 relevant branched oligosaccharides, such as sialyl Lewis(x), as well as sulfated glycosaminoglycan-l

182 -long glass fibers, and the selectin ligand, sialyl Lewis(x), was coupled to latex microspheres.

183 nd CD11b are all required for PMN binding to sialyl Lewis(x)-bearing LS174T cells at high shear (800

184 In contrast, sialyl Lewis(x)-low HCT-8 cells fail to aggregate with P

185 test the hypothesis that plasma C1INH bears sialyl Lewis(x)-related moieties and therefore binds to

186 demonstrated that plasma C1INH does express sialyl Lewis(x)-related moieties on its N-glycan as dete

187 provide functional oligosaccharides such as sialyl Lewis(X).

188 -detectable glyconanoparticles conjugated to sialyl Lewis(X).

189 uring selectin recognition, since sLe(X) and sialyl Lewis-a (sLe(a)) were approximately 5-7-fold poor

190 binding of simple oligosaccharides based on sialyl Lewis-X (sLe(X)) and complex molecules with the c

191 amine structure (Galbeta1,4GlcNAc) to create sialyl Lewis-X (sLe(X)) and related sialofucosylated gly

192 nalysis demonstrate the presence of both the sialyl Lewis-X (sLe(X)) and the di-sialylated T-antigen

193 rks that participate in the formation of the sialyl Lewis-X (sLe(X)) epitope on O-glycans linked to a

194 r conventional Hbonds in the pentasaccharide sialyl Lewis-X (sLe(X)-5) between 5 and 37 degrees C in

195 inhibitor to reduce O-linked glycosylation, sialyl Lewis-X formation, and leukocyte adhesion via the

196 t adhesion on SEC apoptosis was tested using sialyl Lewis-X oligosaccharide (sLe(x)), a natural ligan

197 Resulting reduction in the sialyl Lewis-X-bearing epitopes on this ligand may reduc

198 rotein production and increased adherence to sialyl-Lewis antigens and mouse gastric tissue.

199 The sabA gene encodes an adhesin that binds sialyl-Lewis antigens on inflamed gastric tissue.

200 Core 2 O-glycans terminated with sialyl-Lewis x (sLe(X)) are functionally important oligo

201 Sialyl-Lewis X (sLe(X)) is a tetrasaccharide that serves

202 -sialylated- and alpha1,3-fucosylated-moiety sialyl-Lewis x (sLe(x)), which modifies the PSGL-1 N ter

203 ro and in vivo because of markedly decreased sialyl-Lewis X/A carbohydrate ligand-binding epitopes on

204 pport the cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemina

205 (AFM) with cantilevers biofunctionalized by sialyl-Lewis(x) (sLe(x)) were employed to investigate Ab

206 s and displays copies of the tetrasaccharide sialyl-Lewis(x) (sLe(X)), as well as a cluster of three

207 -selectin glycoprotein ligand-1 [PSGL-1] and Sialyl-Lewis(x) [SLeX]) to rapidly target inflamed tissu

208 detect binding of the SabA adhesin domain to sialyl-Lewis(X) and Lewis(X) but not to Lewis(A), Lewis(

209 es the binding of the SabA adhesin domain to sialyl-Lewis(X) and Lewis(X).

210 eu5Acalpha2-3Galbeta1-4GlcNAc, including the sialyl-Lewis(x) motif and structures containing 6-sulfog

211 ass spectrometric analyses revealed that the sialyl-Lewis(x) sequence [NeuAcalpha2-3Galbeta1-4(Fucalp

212 Thus, the sialyl-Lewis(x) sequence represents the major carbohydra

213 inhibited by glycoconjugates terminated with sialyl-Lewis(x) sequences or by antibodies directed agai

214 We have shown that C1INH expresses the sialyl-Lewis(x) tetrasaccharide on its N-linked glycan,

215 egrins or selectin carbohydrate ligands (eg, sialyl-Lewis(x)).

216 bind tightly to sugar moieties Lewis(B) and sialyl-Lewis(X), respectively, on the surface of epithel

217 ell binding is because of markedly decreased sialyl-Lewis(x/a) (sLe(x/a)) carbohydrate ligand-binding

218 Results demonstrate that 1) the sLe(X) (sialyl-Lewis-X) epitope is expressed in P-selectin glyco

219 oll" (via interactions between selectins and sialyl-Lewis-x), and then firmly adhere to the vascular

220 features with the soluble E-selectin ligand, sialyl Lewisx (sialyl Lex).

221 The selectins bind weakly to sialyl Lewisx (SLe(X))-like glycans, but with high-affin

222 ed that Ply has the highest affinity for the sialyl LewisX (sLeX) structure, with a K(d) of 1.88 x 10

223 oproteins containing active moieties such as sialyl Lewisx (sLex) with P-selectin expressed on endoth

224 selectin ligand expression and expression of sialyl Lewisx (sLex), as defined by HECA-452 (cutaneous

225 he selectin-reactive oligosaccharide moiety, sialyl Lewisx (sLex), as N-linked oligosaccharide adduct

226 terminus and by the crucial tetrasaccharide sialyl LewisX produces dramatic changes in the failure k

227 ly related to the soluble E-selectin ligand, sialyl Lewisx, and is selectively expressed in skin, lym

228 bivalent functional oligosaccharides such as sialyl Lewisx, which provide much better carbohydrate li

229 which makes possible the biosynthesis of the sialyl-Lewisx (sLex) tetrasaccharide (NeuNAcalpha2-3Galb

230 he soluble E-selectin ligand, sialyl Lewisx (sialyl Lex).

231 c oligosaccharide sequences, sialyl-Lea- and sialyl-Lex-active, could be resolved by HPLC as fluoresc

232 binding affinity to SNA, while alteration in sialyl linkage and terminal sialic acid structure compro

233 and non-natural sialic acid forms, different sialyl linkages and different glycans that link to the s

234 carbohydrate motifs, allowing distinction of sialyl linkages and investigation pertaining to the effe

235 Differentiation between the sialyl linkages is often critical to understanding biolo

236 seudotype with a negatively charged sulfated sialyl lipid (NMSO3) displayed a approximately 4-fold-hi

237 and replication, that is, NMSO3, a sulfated sialyl lipid compound, and ribavirin, respectively.

238 in outer membrane presentation of unnatural sialyl-LOS.

239 t express a CD44 glycoform bearing alpha-2,3-sialyl modifications.

240 c residues and is equidistant from the large sialyl motif in both polysialyltransferases.

241 ted in the loss of glycoforms terminating in sialyl-N-acetylhexosamine and the appearance of higher m

242 ncludes N-terminal synthetase and C-terminal sialyl O-esterase domains.

243 Mono-sialyl O-glycans represented approximately 66% of the gl

244 SLex oligosaccharide targeting relative to a sialyl oligosaccharide control.

245 to the kidney with 2-3-fold selectivity over sialyl oligosaccharide controls, whereas monovalent and

246 and tetraantennary SLex oligosaccharides or sialyl oligosaccharide controls.

247 g that relied on multivalent ligation of BCR sialyl-oligosaccharide.

248 ialic acids modification for the analysis of sialyl oligosaccharides and glycopeptides.

249 libration of 1 and mass spectral analysis of sialyl phosphates suggest that the 4O,5N-oxazolidinone a

250 oited for the enzymatic synthesis of diverse sialyl products.

251 dicals) poor kinetic selectivity of anomeric sialyl radicals is discussed in terms of the planar pi-t

252 teins that reduced virus binding to alpha2,3-sialyl receptor and NA activity.

253 ants bind a broader range of alpha2-3-linked sialyl receptor sequences of a type expressed on ciliate

254 nding affinity for synthetic alpha2,6-linked sialyl receptor.

255 tor-binding domain determines the species of sialyl receptors recognized by influenza viruses.

256 igenic phenotype also impacted HA binding to sialyl receptors that are usually present in the human r

257 together with decreasing binding to alpha2,6 sialyl receptors.

258 rases (polySTs) responsible for polymerizing sialyl residues from donor CMP-sialic acid are not homol

259 We previously reported that removal of sialyl residues primed PBMCs to respond to bacterial LPS

260 acid units on their surfaces, mimicking the sialyl-rich mucin layer coating epithelial cells and the

261 electively binds MUC1 that carries the Tn or sialyl (S)Tn glycan.

262 ta1-3[NeuAcalpha2-6]GalNAc-R), followed by 3-sialyl T antigen (NeuAcalpha2-3Galbeta1-3GalNAc-R), stru

263 The occurrence of T- and sialyl T-antigen varied in bovine and ovine reproductive

264 n of mucin origin, with terminal fucose, the sialyl T-antigen, and N-linked oligosaccharides identifi

265 significant amounts of elaborated O-glycans (sialyl-T and disialyl-T) which were inhibited upon treat

266 mine [NeuAcalpha(2-3)Galbeta(1-4)GlcNAc] and sialyl-T antigen [NeuAcalpha(2-3)Galbeta(1-3)GalNAc], wh

267 f these seven strains adhered via T antigen, sialyl-T antigen, and/or lactosamine sequences.

268 3)GalNAc], whereas the BR of GspB only bound sialyl-T antigen.

269 of the Golgi, resulting in the formation of sialyl-T antigen.

270 r marker MUC1 carrying one or more Tn, T, or sialyl-T antigens.

271 Conversely, specific inhibition of MAG or sialyl-T MUC1 partially blocked adhesion.

272 DC with sialyl-Thomsen-Friedenreich antigen (Sialyl-T) suggests that BoNT/DC recognizes only the sial

273 lls, bearing MUC1 that predominantly carries sialyl-TF, only demonstrated an adhesive response to gal

274 Two N-acetyl 4O,5N-oxazolidinone-protected sialyl thioglycosides epimeric at the 7-position have be

275 Sialyl Thomsen-nouveau (STn) is a tumor-associated carbo

276 The co-crystal structure of BoNT/DC with sialyl-Thomsen-Friedenreich antigen (Sialyl-T) suggests

277 saccharide motif alone, corresponding to the sialyl-Thomsen-Friedenreich antigen, that represents the

278 mor-associated carbohydrate antigens, Tn and sialyl Tn (STn), result from somatic mutations in the ge

279 d mucin in PanINs is an early event, whereas sialyl Tn expression is a late event in the recently def

280 and mucin-associated tumor antigens (Nd2 and sialyl Tn) in these precursor lesions.

281 on of mucin-associated carbohydrate antigen, sialyl Tn, was markedly increased only in PanlN-3 and in

282 ing protein 1) showed significant binding to sialyl-Tn (Neu5Acalpha2-6-GalNAc), a tumor marker associ

283 ated sialylated O-glycans, the disaccharide, sialyl-Tn (sialic acid alpha2,6GalNAc), is expressed by

284 ied with immunoperoxidase staining of CD11b, sialyl-Tn (sTn) antigen (Ag), and gamma immunoglobulin (

285 and discrimination of the cancer-associated sialyl-Tn (STn) antigen was developed by using Sambucus

286 Finally, the presentation of the sialyl-Tn epitope and/or more extended structures that i

287 ns of certain mucins and weak binding to the sialyl-Tn epitope.

288 A-encoding ST6GalNAc-I and the expression of sialyl-Tn is evident, demonstrating that the expression

289 large scale production of MUC1 carrying 83% sialyl-Tn O-glycans.

290 vident, demonstrating that the expression of sialyl-Tn results from switching on expression of hST6Ga

291 selectively bound Neu5Acalpha2-6GalNAcalpha (sialyl-Tn) allowing its formal designation as Siglec-6.

292 Galbeta1-4GlcNAc and that Siaalpha2-6GalNAc (sialyl-Tn) is rare in mice.

293 u5Gc incorporation into the carcinoma marker Sialyl-Tn, and is the first example of such a novel mech

294 lNAc-II) always results in the expression of sialyl-Tn.

295 S were characterized for their activity in a sialyl transfer assay.

296 f genes encoding proteins with homology to a sialyl transferase (cstII) and a putative N-acetylmannos

297 not exactly co-locate with the Golgi marker sialyl transferase (ST)-mRFP, nor with the t-SNAREs Memb

298 e fused the signal anchor sequences of a rat sialyl transferase and a human galactosyl transferase al

299 lysosomal-associated membrane protein 1, and sialyl transferase are not recruited.

300 ly charged version binds the important alpha-sialyl unit with K1 approximately 1300 m(-1) .